Increasing healthcare price transparency is a strategic objective of CMS, which has finalized rules regulating providers of COVID-19 tests.
New COVID-19 Testing Price Transparency Requirements Effective Immediately
Category: For Laboratories
Discover the latest news, trends, and best practices in revenue cycle management for lab and diagnostic providers, including coding, billing, and collections.
Government Takes Action to Ensure Coverage of COVID-19 Vaccine
CMS helping providers and insurers prepare for swift vaccine administration
COVID-19 Testing Payments and Regulations: What Labs Need to Know
Announcements support faster testing and tighter regulations around reporting
How to Bill for Medicare Add-On Payment for COVID-19 Diagnostic Tests
What you need to know to maximize reimbursement
Larger Payments for Labs Producing Faster COVID-19 Results
CMS incentivizes labs to complete high throughput COVID-19 tests quicker
The Centers for Medicare and Medicaid Services (CMS) recently announced starting January 1, 2021, Medicare will pay $100 to laboratories that complete high throughput COVID-19 diagnostic tests within two calendar days of the specimen being collected. Also effective January 1, 2021, for laboratories that take longer than two days to complete these tests, Medicare will pay $75.
COVID-19 Test Pricing: Know the Facts, Protect Your Lab’s Reputation
Concerns about test price gouging may lead to greater scrutiny of costs
Women Among the Hardest Hit Financially by COVID-19 Pandemic
Hospitals, Health Systems and Labs can tailor billing to help ease healthcare burden
UHC Deadline for Lab Test Registry Delayed Indefinitely
College of American Pathologists Presses UHC to Extend Delay
Navigating Reimbursement for Liquid Biopsy Cancer Testing
Thirty-eight percent of private payers now cover some type of ctDNA-based panel testing. Is your lab aware of evolving payment policies?
COVID-19: Insurers Exempt from Covering Workplace Testing
Must Cover “Medically Appropriate” Tests Only
The rapid rollout in March of the federal FFCRA (Families First Coronavirus Response Act) and CARES (Coronavirus Aid, Relief and Economic Security Act) Acts – and specifically section 6001 of the FFCRA, which defines requirements for insurers – has left providers, labs and insurers uncertain, at times, of their respective responsibilities for COVID-19 testing.
